Compugen Ltd (NAS:CGEN)
$ 1.71 -0.02 (-1.16%) Market Cap: 146.49 Mil Enterprise Value: 57.51 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 53/100

Compugen Ltd at JMP Securities Life Sciences Conference Transcript

Jun 15, 2022 / 01:00PM GMT
Release Date Price: $1.67 (+6.37%)
Ren Benjamin
JMP Securities LLC - Analyst

(audio in progress) JMP Securities Life Sciences Conference. It's my pleasure to introduce Compugen. Presenting for the company is Ari Krashin.

And I'm Ren Benjamin. I'm one of those senior analysts here in the biotech division. And Compugen is one of the companies that we cover. And a lot of our coverage has to do with oncology. And Compugen really, in our view, exemplifies some of our coverage universe.

And so here to tell us more, Ari, take this away.

Ari Krashin
Compugen Ltd. - CFO & COO

Thank you very much, Reni. Good morning. Thank you for having us in this conference. My name is Ari Krashin. I am the CFO and COO. With me, my colleague, Dr. Henry Adewoye, the CMO.

Okay. So Compugen, we are a clinical-stage cancer immunotherapy company, pioneers in computation on target discovery.

Now when you come to think about it, the thing I like about Compugen, among others obviously, and when we come to present year after year in conferences such as this one and others, it's never

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot